RxDoctor Payments Data

Jerome Wilson, PA

Surgical · Dyer, INNPI 1588765010

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Teleflex LLC at 26.8% of the total. 2025 is the largest year on record at $264, more than ten times the $15 reported in 2021.

$516in general payments, 2019–2025

Across 13 payments — averaging $39.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$138
  • Progenics Pharmaceuticals, Inc.$120
  • Johnson & Johnson$69
  • Boston Scientific$53
  • Myriad Genetic Laboratories, Inc.$29
  • Astellas Pharma US Inc$21
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$516 in reported general payments places this provider in the 55th percentile of 130 surgical providers in Indiana.

See all surgical providers in Indiana

Medicare billing

Part B allowed, 2024
$36,083
Medicare patients
277
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron56$42,206
GemtesaVibegron41$26,817
Tamsulosin Hcl395$5,204
Oxybutynin Chloride ErOxybutynin Chloride123$3,526
Solifenacin Succinate16$2,938
Desmopressin Acetate15$2,172
Bethanechol Chloride34$2,042
Finasteride129$1,480
Estradiol31$1,370
Alfuzosin Hcl ErAlfuzosin Hcl25$457
Cephalexin29$379
Oxybutynin Chloride20$274
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$251
Ciprofloxacin Hcl11$142
Sildenafil Citrate14$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$21$42,20656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 130 surgical providers in Indiana.

Other surgical in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →